VELA-TEEN Trial
Phase 3
35
about 1.2 years
12–17
18 sites in AR, CA, DC +11
What this study is about
Researchers are testing a treatment called sonelokimab to see how it works and if it's safe for adolescents with hidradenitis suppurativa (HS). The trial will last about 452 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Sonelokimab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Primary: Adverse events (AEs) following treatment with sonelokimab in adolescents, Discontinuation of sonelokimab treatment due to AEs, Pharmacokinetics (PK) of sonelokimab in adolescents
Secondary: Numerical Rating Scale (NRS) 30